ChinaChina Patent OfficeCNIPAPatent LawUpdates and Changes
10 November 2023

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

by
Ms. Yolanda Wang
Ms. Jennifer Che

On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see our previous article summarizing the draft Implementation Rules). Considering the 4th Amendment of the new Chinese Patent Law was passed in October 2020, we have certainly been waiting a long time for more details about how this law will be implemented.

This document is not publicly available yet. However, the announcement provides a summary of key highlights:

Key Highlights:

  • China will continue to enhance protection of IP rights, with a goal of further refining the patent application and examination systems to improve China’s standards in patent innovation, application, protection, management, and related services.
  • China will continue efforts to strengthen alignment with relevant international treaties.
  • The Regulations affirm that the patent law plays a pivotal role in promoting technological innovation and the development of new industries and markets.
  • China will initiate multiple forms of public awareness campaigns on IP Rights to foster a legal environment that supports and safeguards innovation.

These high level statements reflect China’s overarching goals for strengthening both IP protection as well as public awareness of IP protection in China. We look forward to seeing the details of the Regulations.

As always, we keep an eye out for updates such as these and will inform you as soon as more details come out. 

Other Articles

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

4 January 2023
Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

11 December 2020
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

Our Past Events

Top crossarrow-right